Institute for Neurodegenerative Disorders

Summary

Institute for Neurodegenerative Disorders is a medical facility located in New Haven, Connecticut. This center is recognized for care of Alzheimer's Disease, Parkinson's Disease, Dementia, Neurodegenerative Diseases, Parkinsonism and other specialties. Institute for Neurodegenerative Disorders is involved with conducting 70 clinical trials across 30 conditions. There are 1 research doctors associated with this hospital, such as David Russell, M.D., Ph.D.

Top PIs

Clinical Trials running at Institute for Neurodegenerative Disorders

Parkinson's Disease

Neurodegenerative Diseases

Loss of Smell

[18F] AV-133 PET Imaging

for Parkinson's Disease

The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \[18F\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).

Recruiting

1 award

Phase 2

Prasinezumab

for Parkinson's Disease

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Recruiting

1 award

Phase 3

4 criteria

Deep Phenotyping

for Parkinson's Disease

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Recruiting

1 award

N/A

8 criteria